Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania and currently employs 528 full-time employees. The company went IPO on 2007-02-06. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Follow-Up Questions
Qui est le CEO de Madrigal Pharmaceuticals Inc ?
Mr. Bill Sibold est le President de Madrigal Pharmaceuticals Inc, il a rejoint l'entreprise depuis 2023.
Quelle est la performance du prix de l'action MDGL ?
Le prix actuel de MDGL est de $421.51, il a increased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Madrigal Pharmaceuticals Inc ?
Madrigal Pharmaceuticals Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de Madrigal Pharmaceuticals Inc ?
La capitalisation boursière actuelle de Madrigal Pharmaceuticals Inc est de $9.3B
Est-ce que Madrigal Pharmaceuticals Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 17 analystes ont établi des notations d'analystes pour Madrigal Pharmaceuticals Inc, y compris 6 achat fort, 13 achat, 2 maintien, 1 vente et 6 vente forte
